ScienceBoard.net caught up to Rajangam, chief medical officer of Nkarta, shortly after a Wednesday plenary session she participated in. She explained Nkarta's approach on allogeneic NK cell therapy, with a particular focus on making these new therapies available more broadly.
NK cells make up about 20% of the normal lymphocytes in the body and are the backbone of Nkarta's technology. The company has leveraged the natural ability of NK cells to target cancer and augmented it with additional functionality to make it a viable cell therapy, Rajangam said.
Learn more by watching the video below.
Copyright © 2021 scienceboard.net